Hospital e Maternidade Dr. Christovão da Gama, Grupo Leforte, Santo André, SP, Brazil; Vascular Surgery, Santa Casa School of Medicine Hospital, SP, Brazil; Hemostasis & Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, IL, USA.
Thrombosis and Atherosclerosis Research Institute and McMaster University, Hamilton, ON, Canada.
Thromb Res. 2019 Dec;184:44-49. doi: 10.1016/j.thromres.2019.09.033. Epub 2019 Oct 23.
This review provides the rationale for dual pathway inhibition with the combination of low-dose rivaroxaban (2.5 mg twice daily) to attenuate thrombin generation and aspirin (100 mg once daily) to reduce platelet activation. Such therapy has been licensed for secondary prevention in patients with coronary or peripheral artery disease.
本综述提供了双重途径抑制的基本原理，联合使用低剂量利伐沙班（2.5 毫克，每日两次）以减弱凝血酶生成，和阿司匹林（100 毫克，每日一次）以减少血小板激活。这种治疗方法已被批准用于冠心病或外周动脉疾病患者的二级预防。
